The Beaufort Securities Reaffirms Speculative Buy Rating for Amryt Pharma PLC (FAST)

The Beaufort Securities Reaffirms Speculative Buy Rating for Amryt Pharma PLC (FAST)

Separately, Stifel Nicolaus restated a buy rating and issued a GBX 60 ($0.77) price objective on shares of Amryt Pharma PLC in a research report on Monday, April 24th.

Beaufort Securities restated their speculative buy rating on shares of Amryt Pharma PLC (LON:FAST) in a research report sent to investors on Tuesday, May 23rd, StockTargetPrices.com reports. Beaufort Securities currently has a GBX 62 ($0.80) price objective on the stock.

Shares of Amryt Pharma PLC (FAST) opened at 2.97 on Tuesday. The firm has a 50 day moving average price of GBX 2.91 and a 200-day moving average price of GBX 2.54. Amryt Pharma PLC has a 52 week low of GBX 1.85 and a 52 week high of GBX 3.90. Amryt Pharma PLC Company Profile

Amryt Pharma plc is a specialty pharmaceutical company. The Company is focused on developing and delivering treatments for patients with rare and orphan diseases. The Company is building a diversified portfolio of proprietary drugs to help address some of rare and debilitating illnesses. The Company‚Äôs lead products include AP 101 and AP102.new TradingView.widget({ “height”: 400, “width”: 625, “symbol”: “LSE:FAST”, “interval”: “D”, “timezone”: “Etc/UTC”, “theme”: “White”, “style”: “1”, “locale”: “en”, “toolbar_bg”: “#f1f3f6”, “enable_publishing”: false, “hideideas”: true, “referral_id”: “2588”});

Receive News & Ratings for Amryt Pharma PLC Daily – Enter your email address below to receive a concise daily summary of the latest news and analysts’ ratings for Amryt Pharma PLC and related companies with our FREE daily email newsletter.

Related posts

Leave a Comment